GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Beneish M-Score
中文

Champions Oncology (Champions Oncology) Beneish M-Score : -2.81 (As of Apr. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.81 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Champions Oncology's Beneish M-Score or its related term are showing as below:

CSBR' s Beneish M-Score Range Over the Past 10 Years
Min: -12.28   Med: -3.26   Max: -1.86
Current: -2.81

During the past 13 years, the highest Beneish M-Score of Champions Oncology was -1.86. The lowest was -12.28. And the median was -3.26.


Champions Oncology Beneish M-Score Historical Data

The historical data trend for Champions Oncology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Beneish M-Score Chart

Champions Oncology Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.12 -3.66 -1.86 -3.13 -3.76

Champions Oncology Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.69 -3.76 -3.35 -3.32 -2.81

Competitive Comparison of Champions Oncology's Beneish M-Score

For the Biotechnology subindustry, Champions Oncology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Beneish M-Score falls into.



Champions Oncology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Champions Oncology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.069+0.528 * 1.1738+0.404 * 2.005+0.892 * 0.9171+0.115 * 0.954
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.165+4.679 * -0.143913-0.327 * 1.3452
=-2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jan24) TTM:Last Year (Jan23) TTM:
Total Receivables was $7.90 Mil.
Revenue was 12.019 + 11.573 + 12.561 + 13.071 = $49.22 Mil.
Gross Profit was 4.17 + 4.955 + 4.877 + 5.733 = $19.74 Mil.
Total Current Assets was $13.20 Mil.
Total Assets was $26.79 Mil.
Property, Plant and Equipment(Net PPE) was $13.07 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.99 Mil.
Selling, General, & Admin. Expense(SGA) was $18.19 Mil.
Total Current Liabilities was $21.97 Mil.
Long-Term Debt & Capital Lease Obligation was $6.44 Mil.
Net Income was -2.53 + -2.071 + -2.566 + -2.561 = $-9.73 Mil.
Non Operating Income was 0.058 + -0.105 + 0.014 + -0.827 = $-0.86 Mil.
Cash Flow from Operations was -0.919 + 0.589 + -3.991 + -0.692 = $-5.01 Mil.
Total Receivables was $8.05 Mil.
Revenue was 12.773 + 14.281 + 13.745 + 12.877 = $53.68 Mil.
Gross Profit was 5.074 + 6.838 + 6.693 + 6.656 = $25.26 Mil.
Total Current Assets was $20.36 Mil.
Total Assets was $36.15 Mil.
Property, Plant and Equipment(Net PPE) was $15.44 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.23 Mil.
Selling, General, & Admin. Expense(SGA) was $17.02 Mil.
Total Current Liabilities was $20.80 Mil.
Long-Term Debt & Capital Lease Obligation was $7.70 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7.895 / 49.224) / (8.053 / 53.676)
=0.160389 / 0.15003
=1.069

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(25.261 / 53.676) / (19.735 / 49.224)
=0.47062 / 0.400922
=1.1738

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (13.198 + 13.069) / 26.787) / (1 - (20.359 + 15.442) / 36.151)
=0.019412 / 0.009682
=2.005

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=49.224 / 53.676
=0.9171

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.231 / (2.231 + 15.442)) / (1.993 / (1.993 + 13.069))
=0.126238 / 0.13232
=0.954

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.187 / 49.224) / (17.023 / 53.676)
=0.369474 / 0.317144
=1.165

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((6.437 + 21.969) / 26.787) / ((7.702 + 20.797) / 36.151)
=1.06044 / 0.788332
=1.3452

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-9.728 - -0.86 - -5.013) / 26.787
=-0.143913

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Champions Oncology has a M-score of -2.81 suggests that the company is unlikely to be a manipulator.


Champions Oncology Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology (Champions Oncology) Business Description

Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093